Geron Corporation: FDA Approval Fuels Stock Price Surge

Geron Today Geron $4.73 +0.84 (+21.59%) 52-Week Range $1.64 ▼ Price Target $6.10 Add to Watchlist The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation NASDAQ: GERN into the spotlight, sparking a surge in Geron's stock price and attracting heightened attention from investors seeking opportunities within the healthcare sector and biotech sector. This momentous achievement marks a turning point for Geron and underscores the company's commitment to developing innovative therapies for ...